199 related articles for article (PubMed ID: 38702301)
1. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
4. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
5. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
[TBL] [Abstract][Full Text] [Related]
7. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
9. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.
Yun MR; Choi HM; Lee YW; Joo HS; Park CW; Choi JW; Kim DH; Kang HN; Pyo KH; Shin EJ; Shim HS; Soo RA; Yang JC; Lee SS; Chang H; Kim MH; Hong MH; Kim HR; Cho BC
EMBO Mol Med; 2019 Dec; 11(12):e10581. PubMed ID: 31633304
[TBL] [Abstract][Full Text] [Related]
10. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
11. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
13. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
14. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
15. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
16. Current Approaches in NSCLC Targeting K-RAS and EGFR.
Aran V; Omerovic J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739412
[TBL] [Abstract][Full Text] [Related]
17. Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
Yoon S; Yang H; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Jung KH; Park SR; Choi EK; Kim SW; Park KS; Lee DH
Cancer Res Treat; 2022 Jul; 54(3):767-781. PubMed ID: 34607394
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
19. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
[TBL] [Abstract][Full Text] [Related]
20. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
